Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2020-12-15 Capital/Financing Update
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and base prospectus related to a securities offering, specifically a public offering of common stock. It includes information about the offering size, pricing, risk factors, use of proceeds, and legal matters. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act of 1933. This type of filing is related to capital raising activities and financing updates rather than financial results, management changes, or regulatory certifications. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, confirming it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2020-12-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes an update on the interim data feedback from a clinical trial (CardiAMP Heart Failure Trial) and plans for a future announcement. It does not contain financial statements or detailed financial analysis. It is not an earnings release, annual report, or interim report. The document is an event update about clinical trial progress and anticipated announcements, typical of a Regulatory Filing (RNS). The document length is about 5,189 characters, which is consistent with a brief report rather than a full financial report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-12-14 English
FORM 4
Director's Dealing
2020-12-01 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2020-12-01 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 1, 2020. It announces a press release regarding the safety profile of the company's Helix Biotherapeutic Delivery System and references an attached press release as Exhibit 99.1. The document does not contain financial statements or detailed financial data but rather serves as a disclosure of a press release event. The length is 4110 characters, which is relatively short and consistent with an announcement rather than a full report. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like earnings release or annual report.
2020-12-01 English
FORM PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is titled as a Proxy Statement for the 2020 Annual Meeting of Stockholders of BioCardia, Inc. The content includes detailed information about the annual meeting, including election of directors, proposals for approval, executive compensation, and other governance matters. It also includes instructions for voting and information about the board of directors and corporate governance. The document is not an announcement of a report but the actual proxy solicitation material sent to shareholders. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement, not just a brief announcement or notice. Therefore, the correct classification is PSI with high confidence.
2020-11-20 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.